Collaboration Agreement with Hitachi Chemical
On July 30, Response Genetics secured a collaboration agreement with Hitachi Chemical Co., Ltd., a leading diagnostics manufacturer in Japan. Hitachi Chemical will begin using the Company's proprietary and patented techniques to extract genetic information from formalin-fixed paraffin- embedded (FFPE) tissue samples collected in Southeast Asia, Australia and New Zealand. As part of this collaboration agreement, Response Genetics will provide Hitachi Chemical with the technical information and assistance necessary to perform the testing services, and the two Companies will divide the revenues. Financial terms of the deal were not disclosed.
Two-Year Research Study Collaboration with UCSF
On August 7, Response announced a two-year research study to develop a diagnostic test kit for pancreatic cancer. The study will combine patient outcomes data with genetic information that it extracts from archival formalin-fixed paraffin-embedded (FFPE) pancreatic tissue samples. The results could potentially lead to the development of assays and diagnostic tests for pancreatic cancer. The study will be conducted in collaboration with the University of California, San Francisco, which will provide the FFPE pancreatic tissue samples for evaluation.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (Nasdaq: RGDX) is engaged in the
research and development of pharmacogenomic cancer diagnostic tests based
on its proprietary and patented technologies. RGI's technologies enable
extraction and analysis of genetic information from genes derived from
tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI
currently generates revenue prima
|SOURCE Response Genetics, Inc.|
Copyright©2007 PR Newswire.